U.S-CHINA TRADE TALKS BEGIN IN PARIS, SETTING STAGE FOR TRUMP-XI SUMMIT. (PHOTO).

Image
 US-China trade talks begin in Paris, setting stage for Trump-Xi summit  U.S. and Chinese officials began high-level trade talks in Paris on Sunday, setting the stage for President Donald Trump’s upcoming visit to Beijing to meet Chinese leader Xi Jinping in about two weeks. The delegations are led by U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng. While the White House has announced Trump’s visit for March 31 to April 2, Beijing has not yet confirmed the dates. Bessent emphasized that the U.S. team aims to secure outcomes that prioritize American farmers, workers, and businesses. Over the two-day talks, the delegations will focus on trade and economic issues of mutual concern. Trump’s visit will be his first to China since his first term in 2017 and follows a one-year truce in the U.S.-China trade war agreed upon last year in Busan, South Korea. Despite the truce, tensions remain, including over a new U.S. trade investigation into 16 trading partners...

TRUMP CALLS FOR NATIONWIDE BAN ON MEDICAL TREATMENTS FOR TRANSGENDER YOUTH (PHOTO).


 Trump calls for nationwide ban on medical treatments for transgender youth

The Trump administration is preparing new federal rules that would sharply restrict gender-affirming medical care for transgender youth across the United States. Under the proposals being drafted by the Department of Health and Human Services, federal Medicaid and CHIP funding would no longer reimburse for medical treatments provided to transgender patients under the age of 18 or 19. An even broader measure would cut off all Medicaid and Medicare funding to hospitals that provide gender-affirming care for minors, effectively pressuring medical facilities nationwide to end such services if they wish to continue participating in federal healthcare programs.

If enacted, the new regulations would make it nearly impossible for young transgender patients to access medical care supported by public health insurance, building on existing state-level bans already in place in more than two dozen states. The proposals follow President Trump’s earlier executive order declaring that the federal government would not support the “transition” of minors and align with the administration’s broader campaign to limit transgender rights in healthcare, education, and the military. Over the past year, federal agencies have withdrawn research funding related to LGBTQ health, disbanded suicide prevention programs tailored to transgender youth, and launched investigations into hospitals offering gender-affirming treatments.

Health policy experts warn that conditioning hospital participation in Medicaid and Medicare on ending gender-affirming care represents an unprecedented expansion of executive authority. Because most hospitals depend heavily on Medicare funding, this move would effectively eliminate youth gender-care programs across the country — regardless of whether patients use public or private insurance. Critics also question the legality of such a rule, warning that it could set a dangerous precedent, allowing any administration to cut off federal funding based on disapproval of certain medical practices. Legal scholars anticipate that, if finalized, the rules would face extensive court challenges over constitutional and administrative law violations.

The administration’s focus on transgender issues extends beyond health regulations. Federal agencies have linked unrelated policy disputes — such as food assistance programs and university funding — to opposition against transgender rights. Transgender service members have been forced out of the military, and colleges have been pressured to adopt restrictive policies on campus gender access. Advocates say these combined efforts have already caused widespread fear and the closure of clinics that still legally provide care.

Although gender-affirming care for minors remains legal under federal law and continues to be supported by major U.S. medical organizations, access is rapidly shrinking. Treatments such as puberty blockers and hormone therapy are endorsed as safe and medically appropriate by professional associations, but political and financial pressures have made them increasingly unavailable. Researchers in Utah recently reaffirmed the safety and benefits of this care, concluding that bans cannot be justified by medical evidence. The upcoming release of the Trump administration’s proposed rules is expected to ignite significant public debate and prompt legal challenges that could determine the future of transgender healthcare access in the United States.


Comments

Popular posts from this blog

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

AMBODE,SOYINKA & OTHERS AT THE OFFICIAL LAUNCH OF LAGOS AT 50 YEARS ANNIVERSARY AGAINST 2017.{PHOTOS}.